Literature DB >> 10908000

History of the methamphetamine problem.

M D Anglin1, C Burke, B Perrochet, E Stamper, S Dawud-Noursi.   

Abstract

Methamphetamine, called meth, crystal, or speed, is a central nervous system stimulant that can be injected, smoked, snorted, or ingested orally; prolonged use at high levels results in dependence. Methamphetamine (MA) is a derivative of amphetamine, which was widely prescribed in the 1950s and 1960s as a medication for depression and obesity, reaching a peak of 31 million prescriptions in the United States in 1967. Until the late 1980s, illicit use and manufacture of MA was endemic to California, but the MA user population has recently broadened in nature and in regional distribution, with increased use occurring in midwestern states. An estimated 4.7 million Americans (2.1% of the U.S. population) have tried MA at some time in their lives. Short- and long-term health effects of MA use include stroke, cardiac arrhythmia, stomach cramps, shaking, anxiety, insomnia, paranoia, hallucinations, and structural changes to the brain. Children of MA abusers are at risk of neglect and abuse, and the use of MA by pregnant women can cause growth retardation, premature birth, and developmental disorders in neonates and enduring cognitive deficits in children. MA-related deaths and admissions to hospital emergency rooms are increasing. Although inpatient hospitalization may be indicated to treat severe cases of long-term MA dependence, optimum treatment for MA abusers relies on an intensive outpatient setting with three to five visits per week of comprehensive counseling for at least the first three months. The burgeoning problems of increased MA use must be addressed by adequate treatment programs suitable for a variety of user types.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908000     DOI: 10.1080/02791072.2000.10400221

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  79 in total

1.  Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine in rats.

Authors:  Sarah White; Elizabeth Laurenzana; Howard Hendrickson; W Brooks Gentry; S Michael Owens
Journal:  Drug Metab Dispos       Date:  2011-06-01       Impact factor: 3.922

2.  "They mess with me, I mess with them": Understanding physical aggression in rural girls and boys from methamphetamine-involved families.

Authors:  Wendy Haight; Jane Marshall; Sydney Hans; James Black; Kathryn Sheridan
Journal:  Child Youth Serv Rev       Date:  2010-10-01

3.  Remediation of Manufactured Methamphetamine in Clandestine Laboratories. A Literature Review.

Authors:  Clyde V Owens; Mark M Mason; David Marr
Journal:  J Chem Health Saf       Date:  2017

Review 4.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

5.  Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting.

Authors:  Nadia Fairbairn; Thomas Kerr; Jane A Buxton; Kathy Li; Julio S Montaner; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2006-12-01       Impact factor: 4.492

Review 6.  The need for speed: an update on methamphetamine addiction.

Authors:  Alasdair M Barr; William J Panenka; G William MacEwan; Allen E Thornton; Donna J Lang; William G Honer; Tania Lecomte
Journal:  J Psychiatry Neurosci       Date:  2006-09       Impact factor: 6.186

7.  The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for hepatitis C infection.

Authors:  Elizabeth C Costenbader; William A Zule; Curtis M Coomes
Journal:  Drug Alcohol Depend       Date:  2007-02-22       Impact factor: 4.492

8.  Striatum and insula dysfunction during reinforcement learning differentiates abstinent and relapsed methamphetamine-dependent individuals.

Authors:  Jennifer L Stewart; Colm G Connolly; April C May; Susan F Tapert; Marc Wittmann; Martin P Paulus
Journal:  Addiction       Date:  2013-12-15       Impact factor: 6.526

9.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

Authors:  Tatiana Lipina; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2009-12-16       Impact factor: 4.530

Review 10.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.